The PreOncology Platform™
The clinical infrastructure that powers the PreOncology Program™.
How the Platform Works
The PreOncology Platform is the clinical operating environment through which the PreOncology Program is delivered. The platform brings genomic, molecular, imaging, and clinical signals together into a single, continuously evolving prevention program, built to be actionable at every level of care.
At its core is the Stage Alpha Operating System™ (patent pending), the computational and clinical backbone that drives personalized risk assessment, surveillance protocol selection, and the resolution of abnormal findings through board-certified oncologist oversight.
The Stage Alpha Operating System
The Stage Alpha Operating System is the clinical decision support system that enables the PreOncology Program to deliver on its core function: detecting cancer at Stage Alpha, the earliest point at which a confident, actionable determination can be made.
It operates across three integrated functions:
Dynamic Risk Engine
Calculates each member’s personalized cancer risk for the most common cancers by integrating whole genome sequencing data with their Precision Risk Assessment. Risk profiles are continuously updated as genomic science evolves, without requiring additional testing.
Protocol Optimization
Translates each member’s risk profile into a personalized surveillance protocol: the right tests, at the right intervals, calibrated to their actual biology rather than population-based age guidelines. Prevention strategies are updated at each surveillance cycle.
Signal Board
Manages and triages abnormal findings through structured clinical workflows. Any signal requiring closer review is escalated to the Signal Board, staffed by board-certified medical oncologists, who review and resolve findings as a clinical panel.
What Sets PreOncology Apart
The PreOncology Platform was designed around a clinical standard, not a consumer one. Every component reflects the rigor expected of a program overseen by board-certified medical oncologists.
Independent Model Validation
Our risk models are validated using large, non-overlapping datasets from cancer centers and national biobanks. The science behind the program meets the evidentiary bar we hold everything else to.
Oncologist-reviewed Findings
The Signal Board is staffed by board-certified medical oncologists at the PreOncology Institute. When a result warrants review, a clinical panel evaluates it, and a clear path forward is provided to the member and their care team.
A Rigorous Technology Evaluation Framework
Every screening technology considered for inclusion in the program is evaluated on a 0-to-15 composite score across five clinical dimensions. Nothing enters the platform because it is new or commercially available. It enters because it meets the gold standard.
Testing Agnostic and Economically Unaligned
PreOncology has no financial relationship with any test manufacturer. Protocol recommendations are driven entirely by clinical evidence and individual patient risk.
Our Data Partners
